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Background. Data on the relationship between core symptoms and daily functioning in adults with attention deﬁcit
hyperactivity disorder (ADHD) are limited. Daily functioning was assessed as part of an open-label extension, and
associations with symptom scores were evaluated.
Method. After a 5-week double-blind study with adults with ADHD receiving osmotic-controlled release oral
delivery system (OROS) methylphenidate (MPH) 18, 36 or 72 mg/day, or placebo, participants were eligible for a
7-week open-label extension in which all patients received OROS MPH. Data for the Conners’ Adult ADHD Rating
Scale – Observer: Screening Version (CAARS-O:SV) (primary endpoint) have been presented previously. Secondary
endpoints included the observer self-reported short version of the CAARS (CAARS-S:S) and the Clinical Global
Impressions – Severity Scale (CGI-S). Daily functioning and quality of life were assessed using the Sheehan Disability
Scale (SDS) and the Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) respectively. In post-hoc
analyses, changes in CAARS-O:SV were evaluated in subgroups. Relationships between symptom and functional
outcomes were evaluated in a multivariate regression analysis.
Results. A total of 370 patients entered the open-label extension. Signiﬁcant improvements from baseline in CAARS-
O:SV were similar regardless of sex, ADHD subtype, prior treatment or psychiatric co-morbidity. Signiﬁcant
improvements from double-blind baseline were also seen for the CAARS-S:S, CGI-S, SDS and Q-LES-Q.
Improvements in the CAARS-O:SV Hyperactivity/Impulsivity subscale were associated with improvements in SDS
total and subscale scores, and in the Q-LES-Q score at open-label endpoint. Improvements in CAARS-O:SV
Inattention subscale and CGI-S scores were not signiﬁcantly associated with functional changes.
Conclusions. Improvements in ADHD symptoms relating to hyperactivity and impulsivity in adults receiving OROS
MPH are associated with improvements in daily functioning and quality of life.
Received 4 November 2010; Revised 18 April 2011; Accepted 3 May 2011; First published online 1 June 2011
Key words: ADHD, adult, daily functioning, methylphenidate, prolonged release, stimulant.
Introduction
In addition to core symptoms of hyperactivity, in-
attention and impulsivity, adults with attention deﬁcit
hyperactivity disorder (ADHD) experience deﬁcits in
executive function, including inhibition of motor im-
pulses, verbal ﬂuency, working memory, planning,
organization and cognitive ﬂexibility (Barkley, 1998;
Woods et al. 2002; Hervey et al. 2004; Roth & Saykin,
2004; Boonstra et al. 2005b; Lijﬃjt et al. 2005). These,
together with the core symptoms, aﬀect daily func-
tioning, leading to impairments in education, work,
relationships and social activities (Kessler et al. 2006;
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ORIGINAL ARTICLEBarkley et al. 2008). It is, however, unclear to what ex-
tent the symptoms contribute to impairments in daily
life.
Stimulant medications such as methylphenidate
(MPH) are highly eﬀective for treatment of the core
ADHD symptoms (Faraone et al. 2004; Medori et al.
2008; Peterson et al. 2008; Adler et al. 2009; Buitelaar
et al. 2009a). There is also evidence that MPH treat-
ment can improve symptoms relating to executive
functioning in parallel with improvements in core
symptoms (Aron et al. 2003; Boonstra et al. 2005a;
Fallu et al. 2006). Few studies, however, have in-
vestigated the relationship between symptomatic
improvement and improvements in daily functioning
in patients with ADHD. A meta-analysis of clinical
trials of atomoxetine in children and adolescents
with ADHD found that symptomatic improvements
(ADHD Rating Scale-IV – Parent Version: Investi-
gator-administered; ADHDRS-IV-Parent:Inv) showed
moderate to strong correlations with improvements in
daily functioning, measured on the Life Participation
Scale (LPS) (Buitelaar et al. 2009b).
The osmotic-controlled release oral delivery system
(OROS) MPH formulation is designed to deliver MPH
in a controlled manner providing extended control of
symptoms during the day. Studies have shown that
once-daily treatment with OROS MPH is eﬀective and
well tolerated for treatment of ADHD in children
and adolescents (Pelham et al. 2001; Wolraich et al.
2001; Swanson et al. 2003), and adults (Biederman
et al. 2006; Medori et al. 2008; Adler et al. 2009;
Buitelaar et al. 2009a). In a 5-week, randomized,
double-blind, placebo-controlled trial [Long Acting
MethylpheniDate in Adult ADHD (LAMDA)], all
three doses of OROS MPH tested led to signiﬁcant
improvements in symptoms of ADHD in adults, as-
sessed using the investigator-rated 18-item Conners’
Adult ADHD Rating Scale – Observer: Screening
Version (CAARS-O:SV) (Medori et al. 2008). OROS
MPH was also associated with statistically signiﬁcant
functional and global improvements, as measured
using the non-disease-speciﬁc Sheehan Disability
Scale (SDS) and the Clinical Global Impressions –
Severity Scale (CGI-S). Regression analyses of data
from LAMDA showed correlations between scores on
the CAARS Hyperactivity/Impulsivity subscale and
both SDS and quality-of-life scores (Ro ¨sler et al. 2011).
In a 7-week open-label extension to LAMDA, sub-
jects who received placebo in the double-blind phase
showed signiﬁcant improvement in CAARS-O:SV
total score after 1 week of treatment in the extension,
with further improvements at weeks 3 and 7, and
CAARS-O:SV total scores continued to improve in
patients who had previously received OROS MPH,
with signiﬁcant changes from baseline at weeks 3 and
7 (Buitelaar et al. 2009a). Here, we present data on
functional and other secondary endpoints from the
LAMDA open-label extension, and also explore the
relationship between symptomatic and functional out-
comes during the cumulative (double-blind and open-
label) 12 weeks of treatment in adults with ADHD.
Method
Study design and patients
Adults with ADHD (n=401) were randomized to re-
ceive OROS MPH (18, 36 or 72 mg/day) or placebo for
5 weeks. Those who completed the double-blind phase
or discontinued study medication as a result of poor
tolerability after o7 days of treatment were eligible to
participate in a 7-week open-label extension during
which they received ﬂexibly dosed OROS MPH in the
range 18–90 mg/day. To maintain blinding from the
double-blind phase, all patients started the open-
label phase at a dose of 36 mg/day (18 mg/day in
Germany), which could subsequently be adjusted to
optimize eﬃcacy and tolerability according to the
clinical judgement of the investigator.
Patients eligible for the initial placebo-controlled
trial were adults (aged 18–65 years) with ADHD ac-
cording to the criteria of DSM-IV and conﬁrmed by the
Conners’ Adult ADHD Diagnostic Interview for DSM-
IV (CAADID). The designs of the initial study and the
open-label extension, together with full inclusion and
exclusion criteria, have been published previously
(Medori et al. 2008; Buitelaar et al. 2009a).
The study was conducted according to Good
Clinical Practice and the ‘Recommendations Guiding
Physicians in Biomedical Research Involving Human
Subjects’ contained in the Declaration of Helsinki. The
study protocol was approved by the ethics committee
at each site. All patients provided written, informed
consent before participating in the study.
Endpoints and analyses
The primary eﬃcacy assessment in the double-blind
and open-label phases was the 18-item CAARS-O:SV
total score (Medori et al. 2008; Buitelaar et al. 2009a).
ADHD symptoms were also assessed using the patient
self-report short version of the CAARS (CAARS-S:S).
During the open-label phase, assessments were made
at weeks 1 and 7 (CAARS-O:SV was also evaluated
at week 3) with a post-study visit 1 week after the
last dose of OROS MPH (whether this occurred in
the open-label or in the double-blind phase). Global
condition was evaluated using the CGI-S, for which
the investigator rates the patient’s severity of illness
on a seven-point scale ranging from 1 (not ill) to 7
(extremely severe). Change in global condition was
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a seven-point scale ranging from 1 (very much im-
proved) to 7 (very much worse) (NIMH, 1985). Daily
functioning was assessed using the SDS, a generic
instrument with three 10-point visual analogue scales
designed to measure the extent to which (i) work,
(ii) social life and leisure activities and (iii) home life
and family responsibilities are impaired (Sheehan et al.
1996). Quality of life was measured using the Quality
of Life Enjoyment and Satisfaction Questionnaire
(Q-LES-Q) Short Form, a 16-item self-administered
questionnaire designed to assess the degree of enjoy-
ment and satisfaction experienced by patients in vari-
ous areas of daily functioning. Patients rated items
concerning physical health, feelings, work, household
duties, work and leisure-time activities and social re-
lationships across ﬁve response categories, ranging
from very poor to very good (Endicott et al. 1993). The
Q-LES-Q has been validated in adults with ADHD
(Mick et al. 2008).
Subjects who were treated in the double-blind
phase could continue into the open-label phase.
Eﬃcacy analyses were performed on the open-label
intent-to-treat (ITT) population, deﬁned as those sub-
jects who received at least one dose of open-label
study medication and had at least one post-baseline
assessment during the open-label phase.
Changes in CAARS-O:SV, CAARS-S:S and Q-LES-Q
were analysed using a paired-samples t test. A re-
gression analysis was performed for each functional
scale on the change from double-blind baseline at the
end of the open-label period, including baseline
score, age, country, double-blind OROS MPH dose (or
placebo), sex, change in CAARS-O:SV Hyperactivity/
Impulsivity subscale score, change in CAARS-O:SV
Inattention subscale score, and change in CGI-S at end
of double-blind. The CAARS-O:SV total score was
found to correlate strongly with the two CAARS-O:SV
subscale scores, and was therefore not included in the
analysis.
Results
Patient disposition
In the double-blind phase, 401 patients received at
least one dose of study medication and 365 patients
(91%) completed the 5-week double-blind study
period. Full details of patient disposition in the
double-blind phase have been published previously
(Medori et al. 2008).
Of the 377 eligible patients, 370 entered the 7-week
open-label extension. The ITT population comprised
369 patients, of whom 93 had received placebo and 276
had received OROS MPH in the double-blind phase.
The mean (¡S.D.) daily dose of OROS MPH in the
open-label phase was 46.5¡14.2 mg (range 18–82 mg)
and the mean maximum dose was 57.6¡18.1 mg
(range 18–108 mg). The overall mean daily dose in the
open-label phase was similar regardless of the original
treatment group (45.6–48.0 mg). The most frequent
maximum doses of OROS MPH in the open-label
phase were 54 mg (36%), 36 mg (26%) and 72 mg
(25%). The most frequent ﬁnal doses in the open-label
extension were 54 mg (34%), 36 mg (29%) and 72 mg
(20%).
In total, 337 patients completed the open-label ex-
tension. Of the 33 patients (8.9%) who withdrew from
the study prematurely, 18 withdrew because of an
adverse event, ﬁve were lost to follow-up, one with-
drew consent, one withdrew because of lack of eﬃ-
cacy, and eight withdrew for other reasons. Baseline
characteristics of the patients who entered the open-
label phase are shown in Table 1.
Eﬃcacy assessments
CAARS-O:SV scores at baseline, double-blind end-
point and open-label endpoint are shown in Table 2.
Patients who switched from placebo to OROS MPH
at the start of the open-label phase experienced im-
provement in total CAARS-O:SV score from double-
blind endpoint after 1 week of treatment with OROS
MPH [mean (¡S.D.) change at week 1=–3.5¡8.5,
p<0.001 v. double-blind endpoint], whereas those
who had previously received OROS MPH showed
signiﬁcant improvement relative to double-blind end-
point from week 3 of the open-label phase onwards
(mean change at week 3=–4.3¡8.2, p<0.001). At
open-label endpoint, the mean changes from double-
blind endpoint in the CAARS-O:SV score were
x8.4¡9.4 and x6.1¡9.3 in the prior placebo and
prior OROS MPH groups respectively (both p<0.001
v. double-blind endpoint; p=0.0073 for between-
group comparison). Similarly, signiﬁcant changes in
CAARS-O:SV Hyperactivity/Impulsivity and Inatten-
tion subscale scores were seen from double-blind
endpoint to open-label endpoint in both the prior
placebo and prior OROS MPH arms (p<0.001 v.
double-blind endpoint for both subscales) (Table 2). In
the post-hoc subgroup analysis, changes in CAARS-
O:SV score from double-blind endpoint to open-label
endpoint were of similar magnitude regardless of
patient subgroup (Table 3).
At week 7 of the open-label extension, signiﬁcant
improvement from double-blind endpoint was ob-
served in the prior placebo and prior MPH groups for
the CAARS-S:S, CGI-S and Q-LES-Q scales (Table 2).
Signiﬁcant improvement in SDS score was also seen
(Table 2), and the results were similar for each of
the three SDS subscales (Fig. 1). Clinically signiﬁcant
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was present in most patients (80–89%) at double-blind
baseline. At open-label endpoint, the percentage of
patients with clinically signiﬁcant disability was sub-
stantially reduced for each of the three SDS subscales
(39–43%). At open-label endpoint, median (range)
CGI-C scores were 2.0 (1–4) and 2.0 (1–5) in the prior
placebo and prior OROS MPH groups respectively.
Post-study visit
One week after the last dose of OROS MPH (post-
study visit), CAARS-O:SV scores worsened signiﬁ-
cantly compared with open-label endpoint in both the
prior placebo [mean (¡S.D.) increase=6.8¡8.3] and
prior OROS MPH (7.8¡9.3) groups (both p<0.001).
CGI-S scores had also worsened signiﬁcantly from
open-label endpoint at the post-study visit, with a
median change of 0.0 and 1.0 in the prior placebo and
prior OROS MPH groups respectively (both p<0.001
v. open-label endpoint).
Regression analysis
Regression analysis performed on the change in the
functional scales from baseline to open-label endpoint
showed that improvement in the CAARS-O:SV
Hyperactivity/Impulsivity subscale at the end of the
double-blind period was associated with functional
improvement at the end of the open-label period for
the SDS total and subscale scores, and the Q-LES-Q
score (Table 4). Neither change in the CAARS-O:SV
Inattention subscale nor change in CGI-S at the end of
the double-blind period was signiﬁcantly associated
with functional outcome at the end of the open-label
period. Overall, the total explained variances of the
change in functional scale from baseline to open-label
endpoint varied from 30% to 39% (Table 2).
Discussion
In this 7-week open-label extension following a
5-week double-blind, placebo-controlled trial, patients
who received OROS MPH 18–90 mg/day experienced
improvements in symptoms of ADHD, functioning
and quality of life regardless of whether they were
initially randomized to OROS MPH or placebo.
These beneﬁts were found to be similar when patients
were categorized according to sex, ADHD subtype,
prior treatment or the presence of psychiatric co-
morbidities. Although the absolute beneﬁts of OROS
Table 1. Baseline demographics of all patients who entered the open-label phase
Prior placebo
(n=93)
Prior OROS MPH
(n=277)
All subjects
(n=370)
Age (years), mean¡S.D. 34.8¡9.6 34.2¡10.5 34.3¡10.3
Sex, n (%)
Male 58 (62.4) 141 (50.9) 199 (53.8)
Female 35 (37.6) 136 (49.1) 171 (46.2)
Race, n (%)
White 91 (97.8) 272 (98.2) 343 (98.1)
Other 2 (2.2) 5 (1.8) 7 (1.9)
Weight (kg), mean¡S.D. 79.8¡18.2 77.4¡16.7 78.0¡17.1
Body mass index (kg/m
2), mean¡S.D. 25.8¡5.4 25.8¡4.8 25.8¡5.0
Age at ADHD diagnosis (years), mean¡S.D. 31.7¡12.6 29.7¡14.1 30.2¡13.8
ADHD subtype, n (%)
Combined 65 (69.9) 194 (70.0) 259 (70.0)
Predominantly inattentive 23 (24.7) 68 (24.5) 91 (24.6)
Predominantly hyperactive–impulsive 2 (2.2) 14 (5.1) 16 (4.3)
Not otherwise speciﬁed 3 (3.2) 1 (0.4) 4 (1.1)
Prior mood and anxiety disorders, n (%)
Currently active 10 (10.8) 35 (12.6) 45 (12.2)
Not currently active 23 (24.7) 88 (31.8) 111 (30.0)
Prior substance use disorder, n (%)
Currently active 0 1 (0.4) 1 (0.3)
Not currently active 12 (12.9) 35 (12.6) 47 (12.7)
ADHD, Attention deﬁcit hyperactivity disorder; OROS, osmotic-controlled release oral delivery system; MPH,
methylphenidate; S.D., standard deviation.
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open-label endpoint (week 12)
Scale
Prior placebo
(n=93)
Prior OROS
MPH (n=276)
CAARS-O:SV total score
Baseline 37.2¡7.2 36.5¡6.9
Double-blind endpoint 29.5¡10.6 24.3¡10.9
Change v. baseline x7.7¡9.9* x12.3¡10.6*
Open-label endpoint 21.1¡10.0 18.2¡9.1
Change v. double-blind endpoint x8.4¡9.4* x6.1¡9.3*
Change v. baseline x16.0¡10.8* x18.3¡10.8*
CAARS-O:SV Hyperactivity/Impulsivity
Baseline 17.1¡5.5 16.9¡5.1
Double-blind endpoint 13.1¡6.4 11.5¡5.9
Change v. baseline x4.0¡5.5* x5.3¡5.7*
Open-label endpoint 9.3¡5.4 8.6¡4.8
Change v. double-blind endpoint x3.8¡5.0* x3.0¡4.8*
Change v. baseline x7.8¡6.0* x8.3¡6.1*
CAARS-O:SV Inattention
Baseline 20.0¡4.3 19.7¡4.1
Double-blind endpoint 16.4¡6.0 12.8¡6.2
Change v. baseline x3.6¡5.2* x6.9¡6.1*
Open-label endpoint 11.8¡6.0 9.6¡5.3
Change v. double-blind endpoint x3.8¡5.0* x3.0¡4.8
Change v. baseline x8.1¡6.1* x10.0¡5.9*
CAARS-S:S
Baseline 51.2¡10.3 50.0¡11.7
Double-blind endpoint 45.8¡14.1 38.0¡15.8
Open-label endpoint 35.2¡14.6 31.1¡14.1
Change v. double-blind endpoint x11.9¡12.9* x7.2¡11.9*
CGI-S
Baseline 5.0 (3–7) 5.0 (1–7)
Double-blind endpoint 5.0 (2–6) 4.0 (1–7)
Open-label endpoint 3.0 (1–6) 3.0 (1–6)
Change v. double-blind endpoint x1.0 (–4 to 1)* x1.0 (–4 to 2)*
SDS
Baseline 19.8¡5.1 19.6¡5.2
Double-blind endpoint 17.6¡5.2 14.5¡7.0
Open-label endpoint 12.6¡6.3 11.8¡6.4
Change v. double-blind endpoint x4.6¡5.8* x2.8¡6.0*
Q-LES-Q
Baseline 48.8¡14.1 49.4¡15.2
Double-blind endpoint 53.4¡15.2 55.9¡16.4
Open-label endpoint 58.2¡16.4 60.3¡16.2
Change v. double-blind endpoint 5.6¡16.1* 4.7¡14.8
CAARS-O:SV, Conners’ Adult ADHD Rating Scale – Observer: Screening Version;
CAARS-S:S, CAARS – Self: Short Version; CGI-S, Clinical Global Impressions –
Severity Scale; SDS, Sheehan Disability Scale; Q-LES-Q, Quality of Life Enjoyment
and Satisfaction Questionnaire; OROS, osmotic-controlled release oral delivery
system; MPH, methylphenidate.
Scores are mean¡standard deviation or median (range).
*pf0.003 v. double-blind baseline.
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patients who were previously untreated, those who
received placebo for 5 weeks in the double-blind phase
had not ‘caught up’ in terms of CAARS-O:SV score at
week 12 with those who had received 12 weeks of
OROS MPH. This may be related to the ﬂexible-dose
design of the open-label phase, and may also be a
result of patients who had the potential for further
improvement receiving ﬁxed, and therefore poten-
tially suboptimal, doses in the double-blind phase. At
a post-study visit 1 week after discontinuation, there
was no evidence of rebound.
The post-hoc regression analysis showed that
improvement in the CAARS-O:SV Hyperactivity/
Impulsivity subscale was more closely associated with
functional improvement (SDS) and improvement in
quality of life (Q-LES-Q) than improvement in the
CAARS-O:SV Inattention subscale. It is possible that
this lack of correlation between observer-reported
inattention and subject-reported functional disability
reﬂects deﬁcits in subjects’ self-observation. After
12 weeks of treatment, no signiﬁcant associations
between change in CAARS-O:SV Inattention score or
CGI-S at double-blind endpoint (week 5) and change
in SDS or Q-LES-Q were observed, although the
change in CAARS-O:SV Hyperactivity/Impulsivity
subscale was signiﬁcantly associated with functional
improvement for all SDS subscales and Q-LES-Q.
These results are consistent with a similar analysis
carried out at week 5 (double-blind endpoint), when
the change from double-blind baseline in the CAARS-
O:SV Hyperactivity/Impulsivity subscale was signiﬁ-
cantly associated with both SDS total score and Q-LES-
Q score (both p<0.001) (Ro ¨sler et al., in press).
In a meta-analysis of four studies of atomoxetine in
children and adolescents with ADHD, a moderate to
strong correlation (r=x0.68) was observed between
changes in the LPS daily functioning scale and the
ADHDRS-IV-Parent:Inv total, although no p value
was provided for this correlation (Buitelaar et al.
2009b). Of the LPS subscales, the Self-control subscale
showed higher correlations than the Happy/Social
subscale with the symptom measures. Regression
analysis showed high sensitivity for functional
measures to changes in symptom severity. Of note,
impairments in daily functioning in children seemed
to be driven by symptoms of inattention, suggesting
that the eﬀect of ADHD symptoms on daily living may
change as individuals move from childhood to adult-
hood.
The magnitude of improvement in SDS score in the
present study compares favourably with that demon-
strated in a 4-year open-label study of atomoxetine,
in which the change in SDS total score was x3.8
(Adler et al. 2008b). Indeed, the improvement in SDS in
the present study was almost as large as that seen in a
12-week open-label study of duloxetine in patients
with major depressive disorder, in which the mean
SDS total score was reduced from 18.7 to 9.5 (Hudson
et al. 2007). Although the SDS has not been validated
Table 3. Change from double-blind endpoint to open-label
endpoint in CAARS total scores in patient subgroups
Subgroup
Prior
placebo
Prior OROS
MPH
Sex
Male
n 58 141
Mean¡S.D. x7.6¡8.6 x5.6¡8.8
p value <0.001 <0.001
Female
n 35 135
Mean¡S.D. x9.7¡10.7 x6.6¡9.8
p value <0.001 <0.001
ADHD subtype
Combined
n 6 193
Mean¡S.D. x9.2¡10.3 x6.6¡9.9
p value <0.001 <0.001
Predominantly inattentive
n 23 68
Mean¡S.D. x6.3¡7.1 x5.1¡8.0
p value <0.001 <0.001
Prior treatment
Treatment-naı ¨ve
n 83 254
Mean¡S.D. x8.1¡9.4 x6.0¡9.3
p value <0.001 <0.001
Non-naı ¨ve
n 10 22
Mean¡S.D. x10.6¡9.7 x7.4¡8.9
p value 0.007 <0.001
Psychiatric co-morbidity
No co-morbidity
n 78 230
Mean¡S.D. x8.6¡9.3 x6.1¡9.0
p value <0.001 <0.001
Co-morbidity present
n 15 46
Mean¡S.D. x7.3¡10.3 x5.9¡10.6
p value 0.016 <0.001
Mood–anxiety disorder
n 10 33
Mean¡S.D. x7.7¡10.2 x4.7¡10.9
p value 0.040 0.018
ADHD, Adult attention deﬁcit hyperactivity disorder;
CAARS, Conners’ Adult ADHD Rating Scale; OROS,
osmotic-controlled release oral delivery system; MPH,
methylphenidate; S.D., standard deviation.
200 J. K. Buitelaar et al.formally in adults with ADHD, it has been validated
in patients with bipolar disorder (Arbuckle et al. 2009),
social anxiety disorder (Hambrick et al. 2004) and
panic disorder (Leon et al. 1992), and has been shown
to be sensitive to treatment eﬀects in patients with
anxiety disorders, depression or premenstrual dys-
phoric disorder (Sheehan & Sheehan, 2008).
In the present study, signiﬁcant improvement
from baseline in quality of life, as measured by the
Q-LES-Q, was observed. These are consistent with the
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Fig. 1. Mean (¡standard deviation) Sheehan Disability Scale (SDS) subscale scores at baseline, double-blind endpoint and
open-label endpoint for patients previously treated with placebo (left panel, n=93) or osmotic-controlled release oral delivery
system (OROS) methylphenidate (MPH) (right panel, n=269). ** p<0.01, *** p<0.001 versus baseline.
Table 4. Regression coeﬃcients of symptomatic improvement and other independent variables on functional improvement. The analysis
was performed for each functional scale on the change from baseline to open-label endpoint including baseline score, age, country,
treatment group, sex, and change in CAARS Hyperactivity/Impulsivity, CAARS Inattention and CGI-S at double-blind endpoint
Functional improvement at open-label endpoint
SDS: Work SDS: Social Life SDS: Family Life SDS: Total Score Q-LES-Q
Symptomatic improvement
at double-blind endpoint
CAARS Inattention 0.0355 (0.3125) 0.0217 (0.4850) x0.0061 (0.8546) 0.0720 (0.4289) x0.3768 (0.1008)
CAARS Hyperactivity/
Impulsivity
0.0945 (0.0039) 0.0750 (0.0111) 0.1181 (0.0002) 0.2517 (0.0031) x0.4650 (0.0282)
CGI-S 0.1792 (0.3590) 0.2465 (0.1498) 0.1582 (0.3905) 0.5312 (0.2929) x0.4476 (0.7228)
Variable
Age 0.0119 (0.3774) 0.0308 (0.1949) 0.0111 (0.3793) 0.1136 (0.1061) 0.0677 (0.4303)
Countrya N.A. (0.6405) N.A. (0.1766) N.A. (0.4743) N.A. (0.4411) N.A. (0.4841)
Treatment: OROS
MPH 18 mg
0.0831 (0.8252) x0.2090 (0.8592) 0.1283 (0.7154) x1.1474 (0.7452) x1.9413 (0.4196)
Treatment: OROS
MPH 36 mg
0.0848 (0.8239) 0.9664 (0.3991) x0.1849 (0.6010) 3.8278 (0.2638) x0.7736 (0.7478)
Treatment: OROS
MPH 72 mg
0.4294 (0.2805) 2.6460 (0.0242) 0.1031 (0.7779) 8.4345 (0.0157) x1.5635 (0.5425)
AgerOROS MPH 18 mg – – – 0.0528 (0.5853) –
AgerOROS MPH 36 mg – – – x0.1159 (0.2212) –
AgerOROS MPH 72 mg – – – x0.2232 (0.0185) –
Sex: Female 0.2727 (0.3103) 0.3852 (0.1043) 0.3754 (0.1428) 1.1392 (0.1113) 0.6127 (0.7221)
Variance (R
2) 0.3289 0.3971 0.3710 0.3514 0.3092
CAARS, Conners’ Adult ADHD Rating Scale; CGI-S, Clinical Global Impressions – Severity Scale; SDS, Sheehan Disability
Scale; Q-LES-Q, Quality of Life Enjoyment and Satisfaction Questionnaire; OROS, osmotic-controlled release oral delivery
system; MPH, methylphenidate; N.A., not available.
Values given are point estimates with p values (for diﬀerence from zero) in parentheses.
aPoint estimates were calculated separately for each participating country.
Functional and symptomatic improvement: correlations in ADHD 201quality of life improvements reported in other studies
in adults with ADHD receiving stimulant medication.
In two 7-week studies in adults with ADHD treated
with mixed amphetamine salts, improvements in
health-related quality of life assessed using the dis-
ease-speciﬁc ADHD Impact Module (AIM-A) were
signiﬁcantly greater than those in subjects receiving
placebo (Spencer et al. 2008a,b). Further analysis
of data from these two studies showed that the im-
provements in quality of life, particularly the Per-
formance and Function subscale of the AIM-A, were
correlated with improvements in executive function
(Brown & Landgraf, 2010). Similarly, 8-week, 14-week
and 6-month studies of adults with ADHD receiving
atomoxetine have shown signiﬁcant improvements
versus placebo using the Adult ADHD Quality of Life
Scale (AAQoL; Matza et al. 2007; Adler et al. 2008a,
2009) or the 36-item Short Form questionnaire (SF-36;
Adler et al. 2006). In the latter study, the SF-36 score
was shown to be signiﬁcantly correlated with CAARS-
O:SV.
Dosing in the open-label phase was ﬂexible,
based on clinical judgement, which more closely re-
ﬂects clinical practice than ﬁxed dosing. The patient
cohort was, however, enrolled according to stringent
inclusion and exclusion criteria, which may limit the
generalizability of the data. In addition, it should be
noted that the regression analysis was carried out on a
post-hoc basis and the results remain to be conﬁrmed in
a prospective study.
In conclusion, the results of this analysis of data
from a randomized, double-blind study and its open-
label extension show that improvements in ADHD
symptoms relating to hyperactivity and impulsivity in
adults receiving OROS MPH are correlated with im-
provements in daily functioning and quality of life.
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